Yong Liu - SINOPHARM GROUP Vice President Chief Legal Advisor
SHTDY Stock | USD 13.31 0.33 2.54% |
President
Mr. Liu Yong serves as President, Executive Director of the Company. Mr. Liu joined the Group in January 2003, he has served as the Groups president since November 2017 and executive director since December 2017. Mr. Liu has over 26 years of working experience, over 23 years of which is management experience in the pharmaceutical and healthcare products industry. Mr. Liu obtained a bachelors degree in science, majoring in business administration of pharmaceutical enterprises, from China Pharmaceutical University in July 1992, a masters degree in business administration from Fudan University in January 2000 and a doctoral degree in social and administrative pharmacy from China Pharmaceutical University in June 2016. Mr. Liu is a chief pharmacist and a practicing pharmacist. Mr. Liu was employed at Shanghai Pharmaceutical Station from July 1992 to July 1999, and served as the deputy general manager at the marketing department of China National Pharmaceutical Group Shanghai Corporation and the deputy general manager of Shanghai Guoda Drug Chain Store Co., Ltd. from July 1999 to April 2003. Mr. Liu was the general manager and secretary of Party Committee of Sinopharm Holding Shenyang Co., Ltd. from April 2003 to November 2009. He served as vice president of the Company from January 2009 to November 2017, secretary to the Board of the Company from October 2016 to November 2017, and has served as chief legal advisor of the Company from January 2014 to December 2017. Mr. Liu is currently the director of Sinopharm Industrial Investment Co., Ltd. and Sinopharm Holding Guoda Drugstores Co., Ltd., and chairman of Sinopharm Lerentang Pharmaceutical Co., Ltd. and China National Accord Medicines Co., Ltd. since 2017.
Age | 54 |
Tenure | 7 years |
Phone | 86 21 2305 2666 |
Web | https://www.sinopharmgroup.com.cn |
SINOPHARM GROUP Management Efficiency
The company has return on total asset (ROA) of 0.0364 % which means that it generated a profit of $0.0364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1319 %, meaning that it generated $0.1319 on every $100 dollars invested by stockholders. SINOPHARM GROUP's management efficiency ratios could be used to measure how well SINOPHARM GROUP manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | PRESIDENT Age | ||
Mark Zacur | Owens Minor | 57 | |
Shana Neal | Owens Minor | 55 | |
Jorge Sahlieh | Cardinal Health | N/A | |
Brian Rice | Cardinal Health | 57 | |
Jeffrey Jochims | Owens Minor | 53 | |
Andrew Long | Owens Minor | 59 | |
Kristin Dietzler | Patterson Companies | N/A | |
James CPA | Henry Schein | 70 | |
Michael Ettinger | Henry Schein | 63 | |
Rob Schlissberg | Cardinal Health | N/A | |
Christopher Pendergast | Henry Schein | 61 | |
George Henriques | Patterson Companies | 64 | |
Kirk Kaminsky | McKesson | N/A | |
David Wilson | Cardinal Health | N/A | |
Timothy Rogan | Patterson Companies | 52 | |
Steve Cunningham | Patterson Companies | N/A | |
Kevin Pohlman | Patterson Companies | 61 | |
Nancy Flores | McKesson | 54 | |
Patricia English | Cardinal Health | 44 | |
Paul Guggenheim | Patterson Companies | 64 | |
Michael Pintek | Cardinal Health | 55 |
Management Performance
Return On Equity | 0.13 | |||
Return On Asset | 0.0364 |
SINOPHARM GROUP LTD Leadership Team
Elected by the shareholders, the SINOPHARM GROUP's board of directors comprises two types of representatives: SINOPHARM GROUP inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SINOPHARM. The board's role is to monitor SINOPHARM GROUP's management team and ensure that shareholders' interests are well served. SINOPHARM GROUP's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SINOPHARM GROUP's outside directors are responsible for providing unbiased perspectives on the board's policies.
Yijian Wu, Non-Executive Director | ||
Xiaojuan Li, Chief Officer | ||
Qingming Yu, Executive Director | ||
Yong Liu, Vice President Chief Legal Advisor | ||
Shuangjun Xu, Non-executive Vice President | ||
Xiuchang Jiang, CFO, Vice President | ||
Wanyong Lian, Non-Executive Director | ||
Maisong Cai, Vice President |
SINOPHARM Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is SINOPHARM GROUP a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.13 | |||
Return On Asset | 0.0364 | |||
Profit Margin | 0.01 % | |||
Operating Margin | 0.04 % | |||
Current Valuation | 16.78 B | |||
Shares Outstanding | 624.13 M | |||
Shares Owned By Institutions | 0.01 % | |||
Price To Earning | 6.27 X | |||
Price To Book | 0.90 X | |||
Price To Sales | 0.01 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for SINOPHARM Pink Sheet Analysis
When running SINOPHARM GROUP's price analysis, check to measure SINOPHARM GROUP's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SINOPHARM GROUP is operating at the current time. Most of SINOPHARM GROUP's value examination focuses on studying past and present price action to predict the probability of SINOPHARM GROUP's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SINOPHARM GROUP's price. Additionally, you may evaluate how the addition of SINOPHARM GROUP to your portfolios can decrease your overall portfolio volatility.